Showing results (331-340 of 726) with videos related to
Sort By:
Pageof 73
Springerplus|June 3, 2015
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancerHelen Kent Chew, Lee Schwartzberg, Suprith Badarinath, et al.Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumorsClinton F Stewart, Michael Tagen, Lee S Schwartzberg, et al.Nature Cell Biology|January 25, 2003
Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulationSylvain Latour, Romain Roncagalli, Riyan Chen, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 2, 2008
Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter studyLee S Schwartzberg, Edward J Stepanski, Mark S Walker, et al.Journal of Cancer Survivorship : Research and Practice|August 28, 2025
Perceived discrimination, patient-provider communication, and quality of life among breast cancer survivors: a mediation analysisFreddie Yang, Xin Hu, Janeane N Anderson, et al.Journal of Medical Economics|August 8, 2013
Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancerPaul J E Miller, Sanjeev Balu, Deborah Buchner, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 31, 2016
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potentialIan Olver, Christina H Ruhlmann, Franziska Jahn, et al.Clinical Lung Cancer|November 11, 2009
Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burdenEdward J Stepanski, Arthur C Houts, Lee S Schwartzberg, et al.Drug Design, Development and Therapy|September 19, 2017
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populationsBernardo Leon Rapoport, Matti Aapro, Martin R Chasen, et al.Health and Quality of Life Outcomes|May 5, 2006
Validation of a patient satisfaction questionnaire for anemia treatment, the PSQ-AnRobert J Nordyke, Chih-Hung Chang, Chiun-Fang Chiou, et al.Pageof 73